ROIV Nasdaq Biotechnology Financials FY2020–FY2025
Roivant Sciences had $8.3M of revenue in fiscal 2025, down 71.6% on the year before. Over five years, revenue changed −19.0% a year on average.
Hi! I read Roivant Sciences’s latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
−71.6%
No. Sales fell 71.6% last year.
Does it make a profit?
−3,629.2%
No. It lost money last year.
Does profit turn into cash?
−9,183.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. Roivant had no borrowings after it sold Dermavant in 2024, so its debt counts as zero from fiscal 2024 (Roivant's fiscal 2025 is the year to March 2026), and with no interest expense in fiscal 2025, interest coverage is blank for that year.
Is it selling more, and how much does it keep?
KIRA · Roivant Sciences had $8.3M of revenue in fiscal 2025, down 71.6% on the year before. Over five years, revenue changed −19.0% a year on average. Its operating margin was −6,235.7%, down 2,782.4 pts: of every 100 in sales, about −6,236 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA · Roivant Sciences lost $300M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA · Free cash flow was −$759M in fiscal 2025, −9,183.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA · Roivant Sciences returned $0.0M to shareholders in fiscal 2025. The diluted share count fell 4.4%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA · In the last 12 months, insiders sold $885M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$885M
12 insiders
Of sales under plans
18%
$155M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $35.11 | $7.0M | Form 4 |
| Oct 1, 2026 | Epperly Melissa BDirector | Sold plan | 17,750 | $36.10 | $0.6M | Form 4 |
| Sep 30, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $36.62 | $7.3M | Form 4 |
| Sep 15, 2026 | Meghan FitzgeraldDirector | Sold plan | 5,112 | $39.74 | $0.2M | Form 4 |
| Sep 15, 2026 | Epperly Melissa BDirector | Sold plan | 4,938 | $39.74 | $0.2M | Form 4 |
| Sep 8, 2026 | Meghan FitzgeraldDirector | Sold plan | 20,000 | $39.90 | $0.8M | Form 4 |
| Aug 28, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $35.77 | $7.2M | Form 4 |
| Aug 21, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 144,756 | $36.48 | $5.3M | Form 4 |
| Aug 20, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 17,519 | $37.30 | $0.7M | Form 4 |
| Aug 19, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 172,899 | $37.17 | $6.4M | Form 4 |
| Aug 18, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 136,942 | $36.73 | $5.0M | Form 4 |
| Aug 17, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 284,707 | $36.25 | $10.3M | Form 4 |
| Aug 14, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 243,177 | $36.23 | $8.8M | Form 4 |
| Jul 27, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $34.95 | $7.0M | Form 4 |
| Jun 30, 2026 | QVT Financial LPDirector by Deputization | Sold | 12,380 | $35.28 | $0.4M | Form 4 |
| Jun 30, 2026 | Keith S ManchesterDirector | Sold | 212,380 | $35.44 | $7.5M | Form 4 |
| Jun 30, 2026 | Meghan FitzgeraldDirector | Sold plan | 10,000 | $34.90 | $0.3M | Form 4 |
| Jun 30, 2026 | Daniel Allen GoldDirector | Sold | 12,380 | $35.28 | $0.4M | Form 4 |
| Jun 29, 2026 | QVT Financial LPDirector by Deputization | Sold | 800,000 | $34.55 | $27.6M | Form 4 |
| Jun 29, 2026 | Keith S ManchesterDirector | Sold | 800,000 | $34.55 | $27.6M | Form 4 |
| Jun 29, 2026 | Epperly Melissa BDirector | Sold plan | 17,750 | $34.38 | $0.6M | Form 4 |
| Jun 29, 2026 | Daniel Allen GoldDirector | Sold | 800,000 | $34.55 | $27.6M | Form 4 |
| Jun 26, 2026 | QVT Financial LPDirector by Deputization | Sold | 625,783 | $34.00 | $21.3M | Form 4 |
| Jun 26, 2026 | Keith S ManchesterDirector | Sold | 625,783 | $34.00 | $21.3M | Form 4 |
| Jun 26, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 500,000 | $34.08 | $17.0M | Form 4 |
| Jun 26, 2026 | Daniel Allen GoldDirector | Sold | 625,783 | $34.00 | $21.3M | Form 4 |
| Jun 25, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 500,000 | $34.13 | $17.1M | Form 4 |
| Jun 24, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $33.16 | $6.6M | Form 4 |
| May 22, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $30.27 | $6.1M | Form 4 |
| Apr 20, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $29.59 | $5.9M | Form 4 |
| Apr 16, 2026 | Matthew GlineCEO, Director | Sold | 289,774 | $29.16 | $8.4M | Form 4 |
| Apr 8, 2026 | Jennifer HumesChief Accounting Officer | Sold | 13,538 | $28.37 | $0.4M | Form 4 |
| Mar 26, 2026 | Meghan FitzgeraldDirector | Sold | 70,000 | $27.45 | $1.9M | Form 4 |
| Mar 17, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $28.24 | $5.6M | Form 4 |
| Mar 16, 2026 | Epperly Melissa BDirector | Sold | 41,861 | $28.68 | $1.2M | Form 4 |
| Feb 23, 2026 | Frank TortiPresident and Vant Chair | Sold plan | 587,390 | $27.51 | $16.2M | Form 4 |
| Feb 20, 2026 | Frank TortiPresident and Vant Chair | Sold plan | 1,012,610 | $27.15 | $27.5M | Form 4 |
| Feb 19, 2026 | Frank TortiPresident and Vant Chair | Sold plan | 1,400,000 | $27.42 | $38.4M | Form 4 |
| Feb 13, 2026 | Keith S ManchesterDirector | Sold | 375,784 | $26.50 | $10.0M | Form 4 |
| Feb 13, 2026 | Daniel Allen GoldDirector | Sold | 375,784 | $26.50 | $10.0M | Form 4 |
| Feb 13, 2026 | QVT Financial LPDirector by Deputization | Sold | 375,784 | $26.50 | $10.0M | Form 4 |
| Feb 13, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $26.49 | $5.3M | Form 4 |
| Feb 12, 2026 | Keith S ManchesterDirector | Sold | 425,000 | $26.75 | $11.4M | Form 4 |
| Feb 12, 2026 | Daniel Allen GoldDirector | Sold | 425,000 | $26.75 | $11.4M | Form 4 |
| Feb 12, 2026 | QVT Financial LPDirector by Deputization | Sold | 425,000 | $26.75 | $11.4M | Form 4 |
| Feb 11, 2026 | Keith S ManchesterDirector | Sold | 425,000 | $26.67 | $11.3M | Form 4 |
| Feb 11, 2026 | Daniel Allen GoldDirector | Sold | 425,000 | $26.67 | $11.3M | Form 4 |
| Feb 11, 2026 | QVT Financial LPDirector by Deputization | Sold | 425,000 | $26.67 | $11.3M | Form 4 |
| Feb 9, 2026 | Mayukh SukhatmePresident & CIO, Director | Sold | 339,441 | $26.47 | $9.0M | Form 4 |
| Jan 12, 2026 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $21.92 | $4.4M | Form 4 |
| Dec 31, 2025 | Mayukh SukhatmePresident & CIO, Director | Sold | 1,018,995 | $21.71 | $22.1M | Form 4 |
| Dec 29, 2025 | Mayukh SukhatmePresident & CIO, Director | Sold | 311,873 | $21.74 | $6.8M | Form 4 |
| Dec 24, 2025 | Eric VenkerPresident & Immunovant CEO | Sold | 75,000 | $22.53 | $1.7M | Form 4 |
| Dec 23, 2025 | Eric VenkerPresident & Immunovant CEO | Sold | 200,000 | $22.45 | $4.5M | Form 4 |
| Dec 23, 2025 | Richard PulikCFO | Sold | 406,731 | $22.43 | $9.1M | Form 4 |
| Dec 17, 2025 | Keith S ManchesterDirector | Sold | 777,332 | $23.07 | $17.9M | Form 4 |
| Dec 17, 2025 | Mayukh SukhatmePresident & CIO, Director | Sold | 26,831 | $23.09 | $0.6M | Form 4 |
| Dec 17, 2025 | QVT Financial LPDirector by Deputization | Sold | 777,332 | $23.07 | $17.9M | Form 4 |
| Dec 17, 2025 | Daniel Allen GoldDirector | Sold | 777,332 | $23.07 | $17.9M | Form 4 |
| Dec 16, 2025 | Daniel Allen GoldDirector | Sold | 917,282 | $23.04 | $21.1M | Form 4 |
| Dec 16, 2025 | QVT Financial LPDirector by Deputization | Sold | 917,282 | $23.04 | $21.1M | Form 4 |
| Dec 16, 2025 | Keith S ManchesterDirector | Sold | 917,282 | $23.04 | $21.1M | Form 4 |
| Dec 15, 2025 | Vivek Ramaswamy10% owner | Sold | 353,745 | $22.05 | $7.8M | Form 4 |
| Dec 15, 2025 | Matthew GlineCEO, Director | Sold | 1,740,000 | $21.68 | $37.7M | Form 4 |
| Dec 12, 2025 | Vivek Ramaswamy10% owner | Sold | 1,975,858 | $21.96 | $43.4M | Form 4 |
| Dec 11, 2025 | Vivek Ramaswamy10% owner | Sold | 774,142 | $21.64 | $16.8M | Form 4 |
| Dec 9, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $20.85 | $4.2M | Form 4 |
| Nov 19, 2025 | QVT Financial LPDirector by Deputization | Sold | 1,300,000 | $20.23 | $26.3M | Form 4 |
| Nov 19, 2025 | Keith S ManchesterDirector | Sold | 1,300,000 | $20.23 | $26.3M | Form 4 |
| Nov 19, 2025 | Daniel Allen GoldDirector | Sold | 1,300,000 | $20.23 | $26.3M | Form 4 |
| Nov 17, 2025 | Vivek Ramaswamy10% owner | Sold | 539,650 | $20.51 | $11.1M | Form 4 |
| Nov 14, 2025 | Vivek Ramaswamy10% owner | Sold | 1,027,670 | $20.33 | $20.9M | Form 4 |
| Nov 13, 2025 | Vivek Ramaswamy10% owner | Sold | 287,283 | $20.81 | $6.0M | Form 4 |
| Nov 7, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 200,000 | $20.22 | $4.0M | Form 4 |
| Oct 17, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 118,418 | $17.06 | $2.0M | Form 4 |
| Oct 16, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 318,282 | $17.05 | $5.4M | Form 4 |
| Oct 15, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 414,683 | $16.93 | $7.0M | Form 4 |
| Oct 13, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 20,727 | $16.25 | $0.3M | Form 4 |
| Oct 9, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 104,940 | $16.30 | $1.7M | Form 4 |
| Oct 8, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 138,602 | $16.20 | $2.2M | Form 4 |
| Oct 7, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 355,161 | $16.15 | $5.7M | Form 4 |
| Oct 6, 2025 | Eric VenkerPresident & Immunovant CEO | Sold plan | 171,396 | $16.34 | $2.8M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA · Roivant Sciences has $4.3B more cash than debt.
Cash, debt and the ratios that show how comfortably Roivant Sciences can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.1B | $1.7B | $6.5B | $4.9B | $4.3B |
| Debt incl. finance leases | $210M | $381M | $431M | $0.0M | $0.0M |
| Net debt / EBITDA | — | — | −1.3x | — | — |
| Debt / equity | 0.1x | 0.3x | 0.1x | 0.0x | 0.0x |
| Interest coverage | −192.0x | −32.4x | 129.3x | −168.3x | — |
| Current ratio | 11.6x | 6.6x | 25.2x | 33.5x | 18.4x |
| Quick ratio | 11.6x | 6.6x | 25.1x | 33.5x | 18.4x |
| Total assets | $2.6B | $2.4B | $7.2B | $5.4B | $5.7B |
| Total liabilities | $524M | $782M | $774M | $250M | $416M |
| Shareholders' equity | $1.7B | $1.2B | $6.0B | $4.7B | $4.5B |
| Net debt (− = net cash) | −$1.9B | −$1.3B | −$6.1B | −$4.9B | −$4.3B |
KIRA · Its return on capital was −62.6%: every 100 invested in the business earned about −63 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA · Roivant Sciences passes 1 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | ✕ | ✕ | ✕ |
| Debt fell relative to assets | ✓ | ✓ | ✕ |
| Current ratio rose | ✓ | ✓ | ✕ |
| Share count didn't rise | ✕ | ✓ | ✓ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | ✓ | ✕ | ✕ |
| F-score | 5 / 8 | 3 / 8 | 1 / 8 |
| Accruals ratio | 106.4% | 10.6% | 8.1% |
| Altman Z'' | 19.06 | 26.49 | 18.07 |
What does the share cost, and how does it compare?
KIRA · At $36.49 a share, the company is worth $26.3B.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
—
Adds net cash of $4.3B and divides by 693.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
KIRA · Roivant Sciences grew sales faster than 0 of its 4 similar companies.
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences ROIV | $26.3B | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | |
| Cytokinetics CYTK | — | 376.6% | −695.4% | −607.5% | — | — | — | Compare → |
| Ligand Pharmaceuticals LGND | $6.6B | 60.4% | 15.3% | 18.2% | 4.9% | 32.3x | 5 | Compare → |
| Krystal Biotech KRYS | $9.6B | 33.9% | 41.5% | 48.6% | 43.6% | 39.0x | 5 | Compare → |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.3x | 5 | Compare → |
Every number, year by year.
Amounts in USD. Hover a ratio’s name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Research and development | $237M | $483M | $454M | $440M | $550M | $682M |
| Operating income | −$1.1B | −$1.4B | −$907M | $4.5B | −$1.0B | −$515M |
| Interest expense | $2.8M | $7.0M | $28.0M | $34.8M | $6.0M | $0.0M |
| Pretax income | −$899M | −$924M | −$885M | $4.6B | −$682M | −$265M |
| Income tax | $1.7M | $0.4M | $4.1M | $21.5M | $48.2M | $133M |
| Net income | −$809M | −$845M | −$1.0B | $4.3B | −$172M | −$300M |
| Diluted EPS | −$1.28 | −$1.26 | −$1.42 | $5.23 | −$0.24 | −$0.54 |
| Diluted shares | 0.63B | 0.67B | 0.71B | 0.83B | 0.73B | 0.69B |
| Cash flow | ||||||
| Cash from operations | −$552M | −$678M | −$843M | −$765M | −$840M | −$750M |
| Capital expenditure | $5.8M | $17.4M | $12.7M | $1.4M | $4.6M | $8.2M |
| Free cash flow | −$558M | −$695M | −$856M | −$767M | −$844M | −$759M |
| Depreciation and amortization | — | $5.9M | $18.9M | $22.0M | $14.1M | $3.3M |
| Stock-based compensation | $85.0M | $565M | $218M | $200M | $289M | $346M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $1.3B | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $1.3B | $0.0M |
| Balance sheet | ||||||
| Cash and short-term investments | $2.1B | $2.1B | $1.7B | $6.5B | $4.9B | $4.3B |
| Total debt | $170M | $210M | $376M | $431M | $0.0M | $0.0M |
| Finance lease liabilities | $0.0M | $0.0M | $5.7M | $0.0M | $0.0M | $0.0M |
| Current assets | $2.2B | $2.1B | $1.8B | $6.7B | $5.0B | $5.2B |
| Current liabilities | $219M | $184M | $272M | $267M | $149M | $281M |
| Inventory | $0.0M | $0.0M | $2.8M | $35.3M | $0.0M | $0.0M |
| Property and equipment, net | $14.7M | $25.9M | $39.1M | $15.3M | $12.1M | $12.0M |
| Total assets | $2.6B | $2.6B | $2.4B | $7.2B | $5.4B | $5.7B |
| Total liabilities | $528M | $524M | $782M | $774M | $250M | $416M |
| Shareholders' equity | $1.8B | $1.7B | $1.2B | $6.0B | $4.7B | $4.5B |
| Margins | ||||||
| Operating margin | −4,500.5% | −2,444.8% | −2,875.9% | 13,746.9% | −3,453.3% | −6,235.7% |
| EBITDA margin | — | −2,434.1% | −2,816.1% | 13,814.3% | −3,404.9% | −6,195.2% |
| Net margin | −3,400.9% | −1,528.9% | −3,200.2% | 13,294.2% | −592.0% | −3,629.2% |
| FCF margin | −2,344.8% | −1,257.4% | −2,715.1% | −2,343.6% | −2,905.2% | −9,183.5% |
| Returns | ||||||
| Return on capital | — | — | −286.2% | — | — | −62.6% |
| Return on capital employed | — | −56.7% | −40.1% | 99.1% | −16.4% | −9.6% |
| Return on equity | — | −48.9% | −71.7% | 122.1% | −3.2% | −6.5% |
| Return on assets | — | −32.7% | −40.6% | 90.5% | −2.7% | −5.4% |
| Growth | ||||||
| Revenue growth | — | 132.3% | −43.0% | 3.8% | −11.2% | −71.6% |
| Net income growth | — | — | — | — | −104.0% | — |
| EPS growth | — | — | — | — | −104.6% | — |
| Share count change | — | 6.3% | 6.4% | 16.6% | −12.7% | −4.4% |
| Financial health | ||||||
| Net debt / EBITDA | — | — | — | −1.3x | — | — |
| Debt / equity | 0.1x | 0.1x | 0.3x | 0.1x | 0.0x | 0.0x |
| Interest coverage | −381.2x | −192.0x | −32.4x | 129.3x | −168.3x | — |
| Current ratio | 10.0x | 11.6x | 6.6x | 25.2x | 33.5x | 18.4x |
| Quick ratio | 10.0x | 11.6x | 6.6x | 25.1x | 33.5x | 18.4x |
| Capital allocation | ||||||
| Capex / revenue | 24.4% | 31.5% | 40.3% | 4.2% | 15.8% | 99.4% |
| Stock comp / revenue | 357.0% | 1,021.9% | 690.7% | 610.2% | 994.8% | 4,190.9% |
| Quality scores | ||||||
| Piotroski F-score | — | — | 1.0 | 5.0 | 3.0 | 1.0 |
| Altman Z'' | 3.9 | 2.1 | −1.4 | 19.1 | 26.5 | 18.1 |
| Accruals ratio | — | −6.5% | −6.7% | 106.4% | 10.6% | 8.1% |
Source: SEC EDGAR XBRL filings (CIK 0001635088). Data updated October 11, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
